专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 从薪酬分布看，A股原料药上市公司董秘年薪平均值为60.84万元。经统计，处于50万以下、50万-100万、100万以上各区间的人数分别为23人、19人、5人，占比分别为49%、40%、11%。 其中，年薪排行前五的董秘分别为国邦医药的龚裕达、赛分科技的王中蕾、科源制药的李春桦、奥锐特的李芳芳、浙江医药的邵旻之。其年薪分别为193.09万元、151.4万元、120万元、117 年薪不足20万的董秘共三人，分别为新天地的谢雨珊、东亚药业的周剑波、欧康医药的曹永强，三人2024年年薪分别为17.42万元、18.75万元、19.07万元。从任职年限看，三位薪酬最低董 从接待投资者次数看，各上市公司接待情况差异较大。经统计，年接待次数小于10次的公司数量为20家，占比43%；接待次数为10次-100次的公司数量为19家，占比40%；接待次数为100次-3 其中，接待投资者次数0次的公司共5家，分别为奥翔药业、川宁生物、新赣江、峆一药业、新天地。 5家年接待投资者次数最多的公司分别为黄山胶囊、河化股份、博瑞医药（维权）、威尔药业、美诺华（维 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有47家上市原料药公司，董事会秘书聘任总体情况如下（部分统计 口径剔除无效数据）。 从董秘的年龄分布来看，介于30-50岁的董秘是市场的中坚力量，占比共计达到60%；50岁以上的董秘 占比为38%；小于等于30岁的董秘群体占比为2%。其中，最年轻的上市公司董秘年仅30岁，为赛分科 技的王中蕾。 年薪不足20万的董秘共三人，分别为新天地的谢雨珊、东亚药业的周剑波、欧康医药的曹永强，三人 2024年年薪分别为17.42万元、18.75万元、19.07万元。从任职年限看，三位薪酬最低董秘均为近两年任 职。 从接待投资者次数看，各上市公司接待情况差异较大。经统计，年接待次数小于10次的公司数量为20 家，占比43%；接待次数为10次-100次的公司数量为19家，占比40%；接待次数为100次-300次的公司 ...

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 从薪酬分布看，A股原料药上市公司董秘年薪平均值为60.84万元。经统计，处于50万以下、50万-100 万、100万以上各区间的人数分别为23人、19人、5人，占比分别为49%、40%、11%。 其中，年薪排行前五的董秘分别为国邦医药的龚裕达、赛分科技的王中蕾、科源制药的李春桦、奥锐特 的李芳芳、浙江医药的邵旻之。其年薪分别为193.09万元、151.4万元、120万元、117.6万元和108.32万 元。从任职年限看，五位最高薪董秘分别于公司任职5年、不足1年、5年、8年、不足2年。 年薪不足20万的董秘共三人，分别为新天地的谢雨珊、东亚药业的周剑波、欧康医药的曹永强，三人 2024年年薪分别为17.42万元、18.75万元、19.07万元。从任职年限看，三位薪酬最低董秘均为近两年任 职。 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有47 ...

Core Viewpoint - Dongya Pharmaceutical (605177.SH) is expected to report a significant loss in the first half of 2025, with net profit projected to be between -28 million to -35 million yuan, contrasting sharply with a profit of 32.47 million yuan in the same period last year [1][2]. Financial Performance - In 2024, the company reported operating revenue of 1.198 billion yuan, a decrease of 11.66% year-on-year [2]. - The net profit attributable to shareholders was -101 million yuan, representing a year-on-year decline of 183.02% [2]. - The net profit after excluding non-recurring gains and losses was -98.41 million yuan, down 191.03% year-on-year [2]. - The net cash flow from operating activities was -157 million yuan [2]. Shareholder Structure - The actual controllers of Dongya Pharmaceutical are Chi Zhengming and Chi Cheng, who together hold significant voting rights in the company [1]. - Chi Zhengming directly owns 41.06% of the shares, while Chi Cheng holds 6.79% directly and has additional influence through a partnership [1]. Fundraising and Use of Proceeds - Dongya Pharmaceutical has raised a total of 1.574 billion yuan through two fundraising rounds since its listing [4]. - The company raised 688 million yuan through the issuance of convertible bonds, with a net amount of approximately 680 million yuan after deducting issuance costs [3]. - The funds raised are allocated for projects including the production of key intermediates for cephalosporin antibiotics and upgrading raw material production [2].

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. is expected to report a significant loss for the first half of 2025, with net profit projected to be between -28 million and -35 million yuan, indicating a decline compared to the same period last year [2][4]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to June 30, 2025 [3]. - The company anticipates a net profit attributable to shareholders of -28 million to -35 million yuan, which represents a loss compared to the previous year's profit of 32.47 million yuan [4][7]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -33 million and -40 million yuan [5]. Group 2: Reasons for Performance Decline - The primary reason for the expected loss is attributed to a decrease in gross profit by approximately 30 million yuan due to changes in product demand influenced by global economic slowdown, industry policies, and intensified competition [10]. - The company plans to recognize an inventory impairment provision of around 30 million yuan, as the net realizable value of certain inventories is expected to be lower than their cost [11]. - Despite the challenges, the company has achieved a significant milestone by obtaining its first formulation approval, which is expected to enhance its product line and competitiveness [9].

Group 1 - The company expects a net profit loss of between 28 million to 35 million yuan for the first half of 2025, with a non-recurring net profit loss of 33 million to 40 million yuan, indicating a year-on-year decline [1] - The main reasons for the profit decline are attributed to changes in product demand due to global economic slowdown, industry policies, and increased competition, leading to a decrease in gross profit of approximately 30 million yuan [1] - The company plans to make a provision for impairment of inventory assets amounting to around 30 million yuan based on prudence [1] Group 2 - The company is actively pursuing an integrated strategy for raw materials and formulations to address challenges in the pharmaceutical industry [2] - In 2023, the company raised nearly 700 million yuan through convertible bonds, investing 350 million yuan in the construction of formulation factory capacity [2] - The company has received acceptance for eight formulation product applications by the end of 2024, with the first formulation product, levofloxacin, approved in June [2] Group 3 - The company's subsidiary, Hangzhou Shanli Biopharmaceutical Technology Co., Ltd., has received the CNAS laboratory accreditation certificate, enhancing its product quality assurance and R&D capabilities [3] - The CNAS accreditation signifies the laboratory's compliance with national standards, which may facilitate international product testing and enhance global market competitiveness [3]

[Key Performance Forecast Data for the Current Period](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E6%83%85%E5%86%B5) The company forecasts a net loss for H1 2025, with attributable net profit between **-28 million and -35 million RMB** and non-recurring adjusted net profit between **-33 million and -40 million RMB** 2025 Half-Year Performance Forecast | Indicator | Estimated Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders | -28 million to -35 million | | Net Profit Attributable to Shareholders After Non-Recurring Items | -33 million to -40 million | - These performance forecast data are preliminary estimates by the company's finance department and have not been audited by a certified public accountant[5](index=5&type=chunk) [Prior Period Operating Performance](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8A%E5%B9%B4%E5%90%8C%E6%9C%9F%E7%BB%8F%E8%90%A5%E4%B8%9A%E7%BB%A9%E5%92%8C%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5) The company reported a profit in H1 2024, with attributable net profit of **32.473 million RMB** and non-recurring adjusted net profit of **26.9332 million RMB**, contrasting the H1 2025 forecast loss 2024 Half-Year Performance (Prior Period) | Indicator | Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders | 32.473 million | | Net Profit Attributable to Shareholders After Non-Recurring Items | 26.9332 million | | Earnings Per Share | 0.29 | [Analysis of Current Period Forecast Loss](index=2&type=section&id=%E4%B8%89%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E4%BA%8F%E7%9A%84%E4%B8%BB%E8%A6%81%E5%8E%9F%E5%9B%A0) The company's shift to a loss is primarily due to a **30 million RMB** decrease in gross profit from reduced market demand and an estimated **30 million RMB** inventory impairment provision [Revenue Side Impact](index=2&type=section&id=%E4%B8%89%E3%80%81%EF%BC%88%E4%B8%80%EF%BC%89%E6%94%B6%E5%85%A5%E7%AB%AF) Reduced terminal demand for some products, influenced by global economic slowdown and competition, led to a year-on-year decrease of approximately **30 million RMB** in gross profit - Due to global economic slowdown, industry policies, intensified competition, supply chain dynamics, and inventory pressure, some of the company's products face reduced demand[8](index=8&type=chunk) - These factors resulted in a year-on-year decrease of approximately **30 million RMB** in the company's gross profit for the current reporting period[8](index=8&type=chunk) [Asset Side Impact](index=2&type=section&id=%E4%B8%89%E3%80%81%EF%BC%88%E4%BA%8C%EF%BC%89%E8%B5%84%E4%BA%A7%E7%AB%AF) Based on prudence, the company plans to accrue approximately **30 million RMB** in inventory impairment provisions for this period, as the net realizable value of some inventory is below cost - The company intends to accrue impairment provisions for assets that may show signs of impairment, primarily inventory[8](index=8&type=chunk) - An estimated **30 million RMB** in inventory impairment provisions is planned for the current reporting period[8](index=8&type=chunk) [Company Strategy and Countermeasures](index=2&type=section&id=%E5%85%AC%E5%8F%B8%E6%88%98%E7%95%A5%E4%B8%8E%E5%BA%94%E5%AF%B9) Despite short-term challenges, the company achieved a major strategic breakthrough with its first preparation approval, advancing its 'API-formulation integration' strategy, and is implementing cost control and organizational reforms - The company obtained its first preparation approval, marking a significant breakthrough in its 'API-formulation integration' development strategy[8](index=8&type=chunk) - The company is actively maintaining market share for its leading products, enriching its product pipeline, and fully advancing the implementation of its preparation business[9](index=9&type=chunk) - Management is implementing cost control and organizational reforms to improve operational quality and enhance product competitiveness[9](index=9&type=chunk) [Risk Warning](index=2&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The company confirms no major uncertainties affecting the accuracy of this performance forecast, emphasizing that the disclosed financial data are preliminary and unaudited - The financial data contained in this announcement are preliminary calculations by the company's finance department based on prudence, and have not been audited by a certified public accountant[10](index=10&type=chunk) [Other Explanatory Notes](index=3&type=section&id=%E4%BA%94%E3%80%81%E5%85%B6%E4%BB%96%E8%AF%B4%E6%98%8E%E4%BA%8B%E9%A1%B9) The company reiterates that the forecast data are preliminary, and final accurate financial figures will be based on the officially disclosed 2025 half-year report, advising investors to be aware of investment risks - The final accurate financial data will be subject to the company's officially disclosed 2025 half-year report, reminding investors to be aware of investment risks[11](index=11&type=chunk)

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-038 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于全资子公司获得中国合格评定国家认可委员会（CNAS） 实验室认可证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江东亚药业股份有限公司（以下简称"公司"）全资子公司杭州善礼生物 医药科技有限公司（以下简称"杭州善礼"）于近日收到中国合格评定国家认可 委 员 会 （ 英 文 名 称 为 " China National Accreditation Service for Conformity Assessment"，以下简称"CNAS"）授予的实验室认可证书，现将相关事宜公 告如下： 一、证书内容 获得机构名称：杭州善礼生物医药科技有限公司 检验检测中心注册号：CNAS L23199 生效日期：2025 年 5 月 20 日 证书主要内容：杭州善礼生物医药科技有限公司分析实验室符合 ISO/IEC 1 ...

Core Viewpoint - East Asia Pharmaceutical (605177) announced that its wholly-owned subsidiary, Hangzhou Shanli Biomedical Technology Co., Ltd., has recently obtained the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment, which enhances the company's credibility and competitive edge in the market [1] Group 1 - The accreditation certificate is effective from May 20, 2025, to May 19, 2031, indicating a long-term recognition of the laboratory's management and technical capabilities [1] - This recognition allows Hangzhou Shanli's analysis laboratory to conduct testing according to national standards, thereby improving product quality and research capabilities [1] - The accreditation is expected to enhance customer trust and contribute to the company's high-quality development, although it will not have a significant impact on the company's current performance [1]

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-037 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 6 月 30 日，累计已有人民币 23,774,000 元 "东亚转债"转为公司 A 股普通股，累计转股股数为 1,153,776 股，占"东亚转 债"转股前公司已发行普通股股份总额的 1.0156%。 未转股可转债情况：截至 2025 年 6 月 30 日，尚未转股的"东亚转债" 金额为人民币 666,226,000 元，占"东亚转债"发行总量的比例为 96.5545%。 本季度转股情况：2025 年 4 月 1 日至 2025 年 6 月 30 日，"东亚转债" 未发生转股情况。 一、"东亚转债"发行上市概况 经中国证券监督管理委员会证监许可〔2023〕1165 号文核准，浙江东亚药 ...